Sanofi
-
FDA approved Sanofi’s eczema drug Dupixent
Oct 20, 2018France’s Sanofi SA said on Friday eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma. Dupixent, co-developed with U.S.-based Regeneron, received... -
Sanofi to refocus two global business units
Sep 13, 2018Sanofi will change the organizational structure of two of its Global Business Units (GBU) to provide a greater focus on its operations in mature markets and across emerging markets. The company will create a new Primary... -
Sanofi Head of Global R&D Elias Zerhouni to retire
Apr 24, 2018Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post by... -
Sanofi to invest €350 million in Canadian vaccine facility
Apr 12, 2018Sanofi is investing €350 million for the construction of a new state-of-the-art vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario. The investment bolsters the company’s Canadian operations and its commitment to advancing... -
Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment
Feb 11, 2018EMA has accepted the application under a special procedure called “Article 58” which allows the EMA to give a scientific opinion, in co-operation with the World Health Organization (WHO), for the evaluation of medicinal products that... -
Sanofi to acquire Bioverativ for $11.6 Billion
Jan 22, 2018With Bioverativ, a leader in the growing hemophilia market, Sanofi enhances its presence in specialty care and leadership in rare diseases, in line with its 2020 Roadmap, and creates a platform for growth in other rare... -
Sanofi ends development of Clostridium difficile vaccine
Dec 3, 2017Sanofi Pasteur, the vaccines business of Sanofi responsible for the program, is informing all investigators, regulatory authorities and trial ethics committees. Following a planned interim analysis, the Independent Data Monitoring Committee (IDMC) for the phase III... -
Sanofi invests €170 million in new vaccine production facility in France
Oct 15, 2017News Hour: Sanofi is investing €170 million to expand a vaccine manufacturing site in Val de Reuil, France. The expansion further strengthens Sanofi’s position as one of the world’s leading seasonal flu vaccine providers. The new... -
Sanofi files suit in the U.S. to defend its patent rights on Lantus®
Aug 13, 2017News Hour: Sanofi announced that it filed a patent infringement suit against Merck Sharp & Dohme Corp. (“Merck”) on August 8, 2017, in the United States District Court for the District of New Jersey. In its suit,... -
Sanofi signs a deal with Ablynx that could earn the Belgian biotech firm as much as 2.4 billion euros
Jul 20, 2017News Hour: French drugmaker Sanofi boosted its early-stage pipeline in immunology on Thursday by signing a deal with Ablynx that could earn the Belgian biotech firm as much as 2.4 billion euros ($2.8 billion). Initial payments...
